FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015288110> ?p ?o ?g. }

• W2015288110 endingPage "1645" @default.
• W2015288110 startingPage "1644" @default.
• W2015288110 abstract "We read with interest the evaluation of the efficacy of telaprevir in patients with well-characterized interferon responses. 1 This study adds to the accumulating body of evidence supporting the use of telaprevir for a wide range of patients with hepatitis C virus (HCV) genotype 1 infection. It remains unclear which patients should be prioritized for retreatment with triple therapy and if this decision is likely to have an effect on patient mortality. We used a number needed to treat (NNT) analysis to determine the benefit of telaprevir-containing triple therapy in preventing liver-related mortality. The NNT approach allows the calculation of a clinically meaningful summary of the effect of a particular treatment 2 and is sensitive to the efficacy of telaprevir and also the underlying risk of mortality by incorporation of the absolute risk reduction (ARR) in its calculation. A meta-analysis of treatment-experienced patients with HCV estimated the annual liver-related mortality rate at 0.81%. 3 In patients with sustained virological response (SVR), that risk is reduced to 0.19%, an ARR of 0.62%. In the study reported by Muir et al., the overall SVR rate was 59%. 1 Thus, in this selected population, the NNT to prevent 1 death per year is 278. Because the mortality estimate from the meta-analysis included studies with follow-up of approximately 5 years, the NNT can be reasonably extrapolated to a 5-year NNT of 56. In treatment-experienced patients with advanced fibrosis, the annual liver-related mortality rate is significantly higher at 2.73%. 3 This is reduced in patients with SVR to 0.52%, an ARR of 2.21%. However, the likelihood of SVR is lower in this group and, although few patients with bridging fibrosis or cirrhosis were included, is likely to be in the region of 40%. 1 Taking these data, the 1-year NNT for patients with advanced fibrosis is 113, and the 5-year NNT is 23. These findings suggest that to have the maximal effect on mortality, the focus should be on treating patients with advanced disease in the first instance. These patients have the most to gain from treatment with triple therapy, and although there are concerns regarding viral resistance, 4 this substantial improvement in outcome should be included in clinical decision making. This analysis cautions against interpretation of SVR rates without consideration of the underlying mortality risks associated with HCV infection and provides clinically useful information for the caring physician when counseling patients regarding retreatment. Ian A. Rowe B.Sc., M.B., Ch.B., M.R.C.P.(UK)* , Matthew J. Armstrong M.B., Ch.B., M.R.C.P. , Diarmaid D. Houlihan M.B., Ch.B. , * Hepatitis C Virus Research Group, University of Birmingham, Birmingham, UK, Center for Liver Research and NHR Biomedical Research Unit, University of Birmingham, Birmingham, UK, Liver and Hepatobiliary Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK." @default.
• W2015288110 created "2016-06-24" @default.
• W2015288110 creator A5023545015 @default.
• W2015288110 creator A5029173327 @default.
• W2015288110 creator A5049287737 @default.
• W2015288110 date "2012-04-19" @default.
• W2015288110 modified "2023-09-24" @default.
• W2015288110 title "Prioritizing treatment experienced patients with hepatitis C infection for treatment with telaprevir: A number needed to treat approach" @default.
• W2015288110 cites W1997514631 @default.
• W2015288110 cites W2008050329 @default.
• W2015288110 cites W2026077821 @default.
• W2015288110 cites W2094986548 @default.
• W2015288110 cites W2165880492 @default.
• W2015288110 doi "https://doi.org/10.1002/hep.25553" @default.
• W2015288110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22212958" @default.
• W2015288110 hasPublicationYear "2012" @default.
• W2015288110 type Work @default.
• W2015288110 sameAs 2015288110 @default.
• W2015288110 citedByCount "1" @default.
• W2015288110 countsByYear W20152881102012 @default.
• W2015288110 crossrefType "journal-article" @default.
• W2015288110 hasAuthorship W2015288110A5023545015 @default.
• W2015288110 hasAuthorship W2015288110A5029173327 @default.
• W2015288110 hasAuthorship W2015288110A5049287737 @default.
• W2015288110 hasBestOaLocation W20152881101 @default.
• W2015288110 hasConcept C126322002 @default.
• W2015288110 hasConcept C179755657 @default.
• W2015288110 hasConcept C203014093 @default.
• W2015288110 hasConcept C2522874641 @default.
• W2015288110 hasConcept C2776408679 @default.
• W2015288110 hasConcept C2776461080 @default.
• W2015288110 hasConcept C2778159067 @default.
• W2015288110 hasConcept C2780040827 @default.
• W2015288110 hasConcept C2908647359 @default.
• W2015288110 hasConcept C44249647 @default.
• W2015288110 hasConcept C67774102 @default.
• W2015288110 hasConcept C71924100 @default.
• W2015288110 hasConcept C82789193 @default.
• W2015288110 hasConcept C99454951 @default.
• W2015288110 hasConceptScore W2015288110C126322002 @default.
• W2015288110 hasConceptScore W2015288110C179755657 @default.
• W2015288110 hasConceptScore W2015288110C203014093 @default.
• W2015288110 hasConceptScore W2015288110C2522874641 @default.
• W2015288110 hasConceptScore W2015288110C2776408679 @default.
• W2015288110 hasConceptScore W2015288110C2776461080 @default.
• W2015288110 hasConceptScore W2015288110C2778159067 @default.
• W2015288110 hasConceptScore W2015288110C2780040827 @default.
• W2015288110 hasConceptScore W2015288110C2908647359 @default.
• W2015288110 hasConceptScore W2015288110C44249647 @default.
• W2015288110 hasConceptScore W2015288110C67774102 @default.
• W2015288110 hasConceptScore W2015288110C71924100 @default.
• W2015288110 hasConceptScore W2015288110C82789193 @default.
• W2015288110 hasConceptScore W2015288110C99454951 @default.
• W2015288110 hasIssue "5" @default.
• W2015288110 hasLocation W20152881101 @default.
• W2015288110 hasLocation W20152881102 @default.
• W2015288110 hasOpenAccess W2015288110 @default.
• W2015288110 hasPrimaryLocation W20152881101 @default.
• W2015288110 hasRelatedWork W1574395574 @default.
• W2015288110 hasRelatedWork W1869877922 @default.
• W2015288110 hasRelatedWork W1977139658 @default.
• W2015288110 hasRelatedWork W1984297957 @default.
• W2015288110 hasRelatedWork W1997514631 @default.
• W2015288110 hasRelatedWork W2008557539 @default.
• W2015288110 hasRelatedWork W2155489902 @default.
• W2015288110 hasRelatedWork W2318862702 @default.
• W2015288110 hasRelatedWork W2331799591 @default.
• W2015288110 hasRelatedWork W2472964144 @default.
• W2015288110 hasVolume "55" @default.
• W2015288110 isParatext "false" @default.
• W2015288110 isRetracted "false" @default.
• W2015288110 magId "2015288110" @default.
• W2015288110 workType "article" @default.